iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments.

Shares of iCAD stock opened at $2.24 on Friday. The firm has a market capitalization of $59.45 million, a PE ratio of -17.23 and a beta of 1.95. The business’s 50-day moving average price is $2. ...

iCAD, Inc. ( NASDAQ:ICAD ) is possibly approaching a major achievement in its business, so we would like to shine some... iCAD ( NASDAQ:ICAD ) Full Year 2024 Results Key Financial Results Revenue ...

iCAD Inc. (ICAD) reported its fourth-quarter 2024 earnings, showcasing a notable performance with earnings per share (EPS) of -$0.03, surpassing the forecasted -$0.06. Revenue reached $5.41 ...

ICAD ($ICAD) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $4,924,050 ...

Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

iCAD partners with RamSoft to integrate AI-powered breast health solutions into radiology platforms, enhancing diagnostic efficiency and patient care. iCAD, Inc. and RamSoft have announced a ...

Revenue: Q4 2024 revenue of $5.4 million; full-year 2024 revenue of $19.6 million. Annual Recurring Revenue (ARR): Total ARR of $9.8 million at the end of Q4 2024, up from $8.8 million in Q4 2023.